# A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients

> **NCT07039383** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 79 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07039383
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-01
- **Primary completion:** 2024-06-18
- **Final completion:** 2024-06-18
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07039383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07039383, "A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07039383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*